Pharma Foods International Co., Ltd. (2929.T)
JPY 934.0
(-0.43%)
JPY 934.0
(-0.43%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 62.14 Billion JPY | -9.37% |
| 2023 | 68.57 Billion JPY | 13.94% |
| 2022 | 60.18 Billion JPY | 28.73% |
| 2021 | 46.75 Billion JPY | 204.51% |
| 2020 | 15.35 Billion JPY | 45.77% |
| 2019 | 10.53 Billion JPY | 32.6% |
| 2018 | 7.94 Billion JPY | 68.2% |
| 2017 | 4.72 Billion JPY | 36.46% |
| 2016 | 3.46 Billion JPY | 59.8% |
| 2015 | 2.16 Billion JPY | 34.14% |
| 2014 | 1.61 Billion JPY | 5.91% |
| 2013 | 1.52 Billion JPY | 24.45% |
| 2012 | 1.22 Billion JPY | 21.69% |
| 2011 | 1 Billion JPY | 4.96% |
| 2010 | 959.1 Million JPY | 30.65% |
| 2009 | 734.09 Million JPY | -9.46% |
| 2008 | 810.83 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 16.14 Billion JPY | 0.64% |
| 2024 Q4 | 14.97 Billion JPY | -3.5% |
| 2024 Q2 | 15.51 Billion JPY | -3.92% |
| 2024 Q3 | 15.51 Billion JPY | 0.06% |
| 2023 FY | 68.57 Billion JPY | 13.94% |
| 2023 Q2 | 18.11 Billion JPY | 6.36% |
| 2023 Q4 | 16.03 Billion JPY | -7.77% |
| 2023 Q1 | 17.03 Billion JPY | 5.55% |
| 2023 Q3 | 17.39 Billion JPY | -3.99% |
| 2022 Q4 | 16.13 Billion JPY | 5.95% |
| 2022 FY | 60.18 Billion JPY | 28.73% |
| 2022 Q3 | 15.22 Billion JPY | -6.08% |
| 2022 Q2 | 16.21 Billion JPY | 28.63% |
| 2022 Q1 | 12.6 Billion JPY | -3.06% |
| 2021 Q2 | 12 Billion JPY | 43.14% |
| 2021 FY | 46.75 Billion JPY | 204.51% |
| 2021 Q4 | 13 Billion JPY | -2.63% |
| 2021 Q3 | 13.35 Billion JPY | 11.24% |
| 2021 Q1 | 8.38 Billion JPY | 97.78% |
| 2020 FY | 15.35 Billion JPY | 45.77% |
| 2020 Q4 | 4.24 Billion JPY | -9.01% |
| 2020 Q3 | 4.66 Billion JPY | 38.63% |
| 2020 Q1 | 3.09 Billion JPY | 16.01% |
| 2020 Q2 | 3.36 Billion JPY | 8.77% |
| 2019 Q2 | 2.61 Billion JPY | 1.44% |
| 2019 FY | 10.53 Billion JPY | 32.6% |
| 2019 Q4 | 2.66 Billion JPY | -0.59% |
| 2019 Q1 | 2.57 Billion JPY | 27.22% |
| 2019 Q3 | 2.68 Billion JPY | 2.58% |
| 2018 Q4 | 2.02 Billion JPY | -9.8% |
| 2018 Q2 | 2.06 Billion JPY | 27.67% |
| 2018 Q1 | 1.61 Billion JPY | 22.18% |
| 2018 FY | 7.94 Billion JPY | 68.2% |
| 2018 Q3 | 2.24 Billion JPY | 8.95% |
| 2017 Q3 | 1.39 Billion JPY | 23.23% |
| 2017 FY | 4.72 Billion JPY | 36.46% |
| 2017 Q4 | 1.32 Billion JPY | -5.17% |
| 2017 Q2 | 1.13 Billion JPY | 28.6% |
| 2017 Q1 | 878.85 Million JPY | -5.95% |
| 2016 FY | 3.46 Billion JPY | 59.8% |
| 2016 Q2 | 1.04 Billion JPY | 62.69% |
| 2016 Q1 | 640.96 Million JPY | -21.52% |
| 2016 Q3 | 842.54 Million JPY | -19.2% |
| 2016 Q4 | 934.48 Million JPY | 10.91% |
| 2015 Q3 | 526.68 Million JPY | 4.2% |
| 2015 Q2 | 505.45 Million JPY | 59.55% |
| 2015 Q1 | 316.79 Million JPY | -50.62% |
| 2015 FY | 2.16 Billion JPY | 34.14% |
| 2015 Q4 | 816.77 Million JPY | 55.08% |
| 2014 Q4 | 641.57 Million JPY | 137.84% |
| 2014 Q1 | 338.87 Million JPY | -45.16% |
| 2014 FY | 1.61 Billion JPY | 5.91% |
| 2014 Q2 | 364.35 Million JPY | 7.52% |
| 2014 Q3 | 269.75 Million JPY | -25.96% |
| 2013 FY | 1.52 Billion JPY | 24.45% |
| 2013 Q1 | 331.92 Million JPY | -30.38% |
| 2013 Q2 | 274.9 Million JPY | -17.18% |
| 2013 Q3 | 299.7 Million JPY | 9.02% |
| 2013 Q4 | 617.96 Million JPY | 106.19% |
| 2012 Q4 | 476.78 Million JPY | 124.42% |
| 2012 FY | 1.22 Billion JPY | 21.69% |
| 2012 Q2 | 267.67 Million JPY | -0.16% |
| 2012 Q3 | 212.45 Million JPY | -20.63% |
| 2012 Q1 | 268.1 Million JPY | -21.96% |
| 2011 Q2 | 229.43 Million JPY | 46.37% |
| 2011 FY | 1 Billion JPY | 4.96% |
| 2011 Q4 | 343.56 Million JPY | 24.06% |
| 2011 Q3 | 276.92 Million JPY | 20.7% |
| 2011 Q1 | 156.74 Million JPY | -43.47% |
| 2010 Q2 | 252.56 Million JPY | 38.75% |
| 2010 FY | 959.1 Million JPY | 30.65% |
| 2010 Q1 | 182.03 Million JPY | 5.79% |
| 2010 Q4 | 277.26 Million JPY | 12.14% |
| 2010 Q3 | 247.24 Million JPY | -2.11% |
| 2009 Q4 | 172.06 Million JPY | -0.9% |
| 2009 Q3 | 173.62 Million JPY | -12.78% |
| 2009 Q1 | 189.35 Million JPY | 0.0% |
| 2009 FY | 734.09 Million JPY | -9.46% |
| 2009 Q2 | 199.05 Million JPY | 5.12% |
| 2008 FY | 810.83 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 98.542% |
| Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 80.243% |
| Shionogi & Co., Ltd. | 435.08 Billion JPY | 85.716% |
| Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | -703.096% |
| Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 58.081% |
| Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 13.737% |
| Eisai Co., Ltd. | 741.75 Billion JPY | 91.622% |
| Morishita Jintan Co., Ltd. | 12.4 Billion JPY | -400.943% |
| Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 56.144% |
| Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 39.596% |
| Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | -12.167% |
| Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | -102.117% |
| Tsumura & Co. | 150.84 Billion JPY | 58.801% |
| Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 17.772% |
| Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | -13.743% |
| Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 72.735% |
| Fuji Pharma Co., Ltd. | 40.88 Billion JPY | -51.99% |
| Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 17.931% |
| KYORIN Holdings, Inc. | 119.53 Billion JPY | 48.008% |
| Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | -1133.075% |
| Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | -32.524% |
| SymBio Pharmaceuticals Limited | 5.58 Billion JPY | -1011.811% |
| MedRx Co., Ltd | 26 Million JPY | -238926.923% |
| Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | -465.5% |
| Solasia Pharma K.K. | 617 Million JPY | -9972.447% |
| Modalis Therapeutics Corporation | - JPY | -Infinity% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 1.108% |
| Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 64.861% |
| Cyfuse Biomedical K.K. | 61.11 Million JPY | -101593.612% |
| Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 95.792% |
| Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | -180.774% |